Syngene International

SYNGENE

NSE

BSE

SectorHealthcare

Loading chart…

Company insights, generated from the most recent coverage.

Q1 FY27 PAT swung to a ₹9 Cr loss from ₹87 Cr profit as EBITDA margin collapsed 990 bps to 15.2% due to major LMCDMO client offtake drop.
₹50 Cr forex hedge loss in Q1 FY27 (vs ₹5 Cr gain YoY) significantly impacted bottom line, highlighting currency risk exposure.
Management guides for single-digit revenue degrowth in FY27 with recovery expected only in H2, extending near-term headwinds.

The Quarter story

The two most recent quarterly results, compared side-by-side.

Syngene’s revenue and market valuation contracted sharply in Q1 FY27 following a major corporate restructuring, with profitability margins halving but operating costs staying lean.

Other direct costs fall from ₹260 Cr in Q4 FY26 to ₹30 Cr in Q1 FY27, keeping input spending lean.

Reported revenue falls from ₹10,587 Cr in Q4 FY26 to ₹761 Cr in Q1 FY27, reflecting a major scale reduction.

Other expenses drop from ₹1,216 Cr in Q4 FY26 to ₹110 Cr in Q1 FY27, reducing overhead pressure.

EBITDA margin drops from 30.8% in Q4 FY26 to 15.2% in Q1 FY27, compressing core profitability.

Depreciation and finance costs fall from ₹1,115 Cr in Q4 FY26 to ₹112 Cr in Q1 FY27, lowering fixed financial burdens.

PAT margin falls from 14.5% in Q4 FY26 to 0.1% in Q1 FY27, leaving almost no net profit buffer.

Net cash reserves decline from ₹18,003 Cr in Q4 FY26 to ₹1,541 Cr in Q1 FY27, tightening liquidity.

About the company

Syngene International Limited is an integrated research, development, and manufacturing services company headquartered in India. It serves global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company operates across four business divisions: Discovery Services, Development Services, Manufacturing Services, and Dedicated Centers. With approximately 6000 scientists, Syngene has facilities spanning 2.2 million sq. ft. in Bangalore, Hyderabad, and Mangalore. It provides end-to-end services within Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). Syngene offers various platforms and services including drug discovery, development capabilities, custom synthesis, process R&D, cGMP manufacturing, and clinical development services. The company has partnerships and collaborations with multiple global pharmaceutical and healthcare companies, expanding its research and manufacturing capabilities over the years.

In the news